Phaseline

Targets › CYP11B1

CYP11B1 (Cytochrome P450 11B1, mitochondrial): drug programs, companies and trials

8 programs from 8 companies in 11 trials: 5 Phase 4, 4 Phase 2, 2 Phase 1; Metabolic and endocrine, Neurology, Cardiovascular; next expected readout Dec 2026.

A cytochrome P450 monooxygenase mainly involved in the biosynthesis of adrenal corticoids. Catalyzes a variety of reactions that are essential for many species, including detoxification, defense, and the formation of endogenous chemicals like steroid hormones. (UniProt, P15538)

Open in Phaseline: the race on CYP11B1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RECORDATI GROUPOsilodrostat (LCI699)
Cytochrome P450 11B1 inhibitor
CYP11B1Phase 4Hypertension; Cushing Syndrome; Mild Autonomous Cortisol Secretion (MACS)Jul 2027
Laikο General Hospital, AthensMetyrapone
Cytochrome P450 11B1, mitochondrial inhibitor
CYP11B1Phase 4Mild Autonomous Cortisol Secretion (MACS)Nov 2027
Washington State UniversityMetyrapone
Cytochrome P450 11B1, mitochondrial inhibitor
CYP11B1Phase 4Shift Work ScheduleMar 2029
IRCCS Azienda Ospedaliero-Universitaria di BolognaMetyrapone
Cytochrome P450 11B1, mitochondrial inhibitor
CYP11B1Phase 4Adrenal Incidentalomas–
West China HospitalMitotane
Cytochrome P450 11A1 inhibitor; Cytochrome P450 11B1 inhibitor
CYP11A1, CYP11B1Phase 2Adrenal Cortical CarcinomaDec 2026
H. LundbeckLu AG13909
11β-hydroxylase inhibitor
CYP11B1Phase 2Cushing's Disease; Congenital Adrenal HyperplasiaAug 2027
Actinogen MedicalXanamem
11β-hydroxysteroid dehydrogenase type 1 inhibitor
CYP11B1Phase 2Dementia ModerateFeb 2028
University Medical Center Groningen[18F]CETO tracer
PET tracer with high specificity for steroidogenic enzymes CYP11B1 and CYP11B2 in adrenal
CYP11B1, CYP11B2Phase 1Primary AldosteronismMay 2027

Conditions

Mild Autonomous Cortisol Secretion (MACS) (2) Dementia Moderate (1) Hypertension (1) Cushing Syndrome (1) Adrenal Cortical Carcinoma (1) Cushing's Disease (1) Congenital Adrenal Hyperplasia (1) Primary Aldosteronism (1) Shift Work Schedule (1) Adrenal Incidentalomas (1)

Modalities

small molecule (6), mixed (2)

Companies

Actinogen Medical (1) RECORDATI GROUP (1) West China Hospital (1) H. Lundbeck (1) University Medical Center Groningen (1) Laikο General Hospital, Athens (1) Washington State University (1) IRCCS Azienda Ospedaliero-Universitaria di Bologna (1)

Related targets

CYP11A1 (1) CYP11B2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.